Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Gregory Rasp who wrote (29597)	12/13/1999 7:41:00 PM
From: celeryroot.com	Read Replies (1) \| Respond to of 32384

funny you shd mention, but i thought all along they were asking for late stage approval. i dont remember them asking for early stage??

To: Gregory Rasp who wrote (29597)	12/13/1999 7:49:00 PM
From: Don S.Boller	Respond to of 32384

Gregory: Appreciate your post...thanks so much. Best, Don

To: Gregory Rasp who wrote (29597)	12/13/1999 9:10:00 PM
From: RXGOLF	Respond to of 32384

<<Just as a little background>> Thanks for the post, it was nicely done and informative! To me, the question is how many dollars will the fourth line of tx for this particular disease generate? Yes, congratulation are indeed in order for a job well done by LGND management. 3 for 3 IS as good as it gets. And yes, off label use COULD be significant IF ABC trials would produce stellar results. Obviously however, if a drug could be used as first line treatment(vs 4th), sales dollars could be many fold greater. IMHO this point is magnified when speaking about a CTCL(relative small pt.pop.)verse a disease such as diabetes(huge pt. pop.). I worry that with the number of shares now afloat, that a 4th line treatment for CTCL might not be exactly what the Dr. had hoped for. Still long LGND, very anxious for tomorrow open, Greg